Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd -

Singapūra - angļu - HSA (Health Sciences Authority)

pfizer private limited - conjugated estrogens (ce) desiccation with lactose @4.29% ce - tablet, sugar coated - 0.3 mg - conjugated estrogens (ce) desiccation with lactose @4.29% ce 0.3 mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 625microgram

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 1.25mg

Malaizija - angļu - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - oestrogens,conjugated -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - calcium carbonate; alendronate sodium; colecalciferol -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - colecalciferol; alendronate sodium; calcium carbonate -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - calcium carbonate,colecalciferol -

Eiropas Savienība - angļu - EMA (European Medicines Agency)

pfizer europe ma eeig - bazedoxifene - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture